Establishment of preanalytical conditions for microRNA profile analysis of clinical plasma samples
Author:
Suzuki KunoORCID, Yamaguchi Tatsuya, Kohda Masakazu, Tanaka Masami, Takemura Hiroyuki, Wakita Mitsuru, Tabe Yoko, Kato Shunsuke, Nasu Motomi, Hashimoto TakashiORCID, Mine Shinji, Serizawa Nobuko, Tomishima Ko, Nagahara Akihito, Matsuda Takahisa, Yamaji Taiki, Tsugane Shoichiro, Saito Yutaka, Daiko Hiroyuki, Yoshikawa Takaki, Kato KenORCID, Okusaka Takuji, Ochiya Takahiro, Yamamoto Yusuke, Yotsui Shoji, Yamamoto Takashi, Yamasaki Tomoyuki, Miyata Hiroshi, Yasui Masayoshi, Omori Takeshi, Ohkawa Kazuyoshi, Ikezawa Kenji, Nakabori Tasuku, Sugimoto Naotoshi, Kudo Toshihiro, Yoshida Keiichi, Ohue Masayuki, Nishizawa Takashi
Abstract
The relationship between the expression of microRNAs (miRNAs) in blood and a variety of diseases has been investigated. MiRNA-based liquid biopsy has attracted much attention, and cancer-specific miRNAs have been reported. However, the results of analyses of the expression of these miRNAs vary among studies. The reproduction of results regarding miRNA expression levels could be difficult if there are differences in the data acquisition process. Previous studies have shown that the anticoagulant type used during plasma preparation and sample storage conditions could contribute to differences in measured miRNA levels. Thus, the impact of these preanalytical conditions on comprehensive miRNA expression profiles was examined. First, the miRNA expression profiles of samples obtained from healthy volunteers were analyzed using next-generation sequencing. Based on an analysis of the library concentration, human genome identification rate, ratio of unique sequences and expression profiles, the optimal preanalytical conditions for obtaining highly reproducible miRNA expression profiles were established. The optimal preanalytical conditions were as follows: ethylenediaminetetraacetic acid (EDTA) as the anticoagulant, whole-blood storage at room temperature within 6 hours, and plasma storage at 4°C or -20°C within 30 days. Next, plasma samples were collected from 60 cancer patients (3 facilities × 20 patients/facility), and miRNA expression profiles were analyzed. There were no significant differences in measurements except in the expression of erythrocyte-derived hsa-miR-451a. However, the variation in hsa-miR-451a levels was smaller among facilities than among individuals. This finding suggests that samples obtained from the same facility could show significantly different degrees of hemolysis across individuals. We found that the standardization of anticoagulant use and storage conditions contributed to reducing the variation in sample quality across facilities. The findings from this study could be useful in developing protocols for collecting samples from multiple facilities for cancer screening tests.
Publisher
Public Library of Science (PLoS)
Subject
Multidisciplinary
Reference46 articles.
1. miRBase: from microRNA sequences to function;A Kozomara;Nucleic Acids Res,2019 2. A Circulating miRNA Signature for Stratification of Breast Lesions among Women with Abnormal Screening Mammograms;SY Loke;Cancers,2019 3. Circulating miRNA panels for specific and early detection in bladder cancer;W Usuba;Cancer Sci,2019 4. Integrated extracellular microRNA profiling for ovarian cancer screening;A Yokoi;Nat Commun,2018 5. MicroRNAs in Cardiovascular Disease;T Barwari;J Am Coll Cardiol,2016
|
|